Scholarlink

<p>Current guidelines recommend treatment of refractory or unexplained chronic cough with neuromodulators such as low-dose morphine, gabapentin or pregabalin. However, their use may be limited by inadequate response or adverse events. New and emerging treatments targeting novel therapeutic avenues (receptors and ion channels involved in cough) may offer improved efficacy and safety. The first of these is the recently approved purinergic 2X3 homotrimeric channel (P2X3) receptor antagonist, gefapixant.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Consider newly available agents for the treatment of refractory or unexplained chronic cough

  • 期刊论文

  • 发表日期：

    2025年5月5日

查看全文
  • Esther S. Kim,
  • Simon Fung

摘要

Current guidelines recommend treatment of refractory or unexplained chronic cough with neuromodulators such as low-dose morphine, gabapentin or pregabalin. However, their use may be limited by inadequate response or adverse events. New and emerging treatments targeting novel therapeutic avenues (receptors and ion channels involved in cough) may offer improved efficacy and safety. The first of these is the recently approved purinergic 2X3 homotrimeric channel (P2X3) receptor antagonist, gefapixant.